Physiologic Treatment of Severe Hypertension in Pregnancy and Postpartum
Copyright © 2023 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved..
We aimed to evaluate physiologic treatment of severe hypertension. This was a retrospective cohort study of pregnant and postpartum patients with severe hypertension (systolic blood pressure [BP] 160 mm Hg or higher or diastolic BP 110 mm Hg or higher) treated with intravenous labetalol or hydralazine at a single tertiary care center between 2013 and 2018. Patients were classified as having physiologic treatment if they had hyperdynamic physiology (pulse pressure 65 mm Hg or higher) and received labetalol or had vasoconstrictive physiology (diastolic BP 100 mm Hg or higher) and received hydralazine. The primary outcome was number of antihypertensive doses to achieve nonsevere BP. Of 1,120 patients included in the analysis, 653 had physiologic treatment and 467 had nonphysiologic treatment, with 16 (1.4%) excluded for inability to classify physiology. Physiologic treatment was associated with fewer antihypertensive doses (1.4±0.9 doses vs 1.6±1.4 doses; adjusted β -0.28, 95% CI, -0.42 to -0.14) and lower odds of medication conversion (2.5% vs 4.7%; adjusted odds ratio 0.48, 95% CI, 0.24-0.93) but no difference in time to nonsevere BP (31 minutes [interquartile range 16-66 minutes] vs 34 minutes [interquartile range 15-76 minutes]; adjusted hazard ratio 1.0, 95% CI, 0.9-1.2). Physiologic treatment of severe hypertension warrants further evaluation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:143 |
|---|---|
| Enthalten in: |
Obstetrics and gynecology - 143(2024), 2 vom: 01. Feb., Seite 277-280 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Davis, Allison M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
26NAK24LS8 |
|---|
| Anmerkungen: |
Date Completed 30.01.2024 Date Revised 20.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/AOG.0000000000005472 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365244457 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365244457 | ||
| 003 | DE-627 | ||
| 005 | 20240420232205.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/AOG.0000000000005472 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1381.xml |
| 035 | |a (DE-627)NLM365244457 | ||
| 035 | |a (NLM)38033320 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Davis, Allison M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Physiologic Treatment of Severe Hypertension in Pregnancy and Postpartum |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.01.2024 | ||
| 500 | |a Date Revised 20.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a We aimed to evaluate physiologic treatment of severe hypertension. This was a retrospective cohort study of pregnant and postpartum patients with severe hypertension (systolic blood pressure [BP] 160 mm Hg or higher or diastolic BP 110 mm Hg or higher) treated with intravenous labetalol or hydralazine at a single tertiary care center between 2013 and 2018. Patients were classified as having physiologic treatment if they had hyperdynamic physiology (pulse pressure 65 mm Hg or higher) and received labetalol or had vasoconstrictive physiology (diastolic BP 100 mm Hg or higher) and received hydralazine. The primary outcome was number of antihypertensive doses to achieve nonsevere BP. Of 1,120 patients included in the analysis, 653 had physiologic treatment and 467 had nonphysiologic treatment, with 16 (1.4%) excluded for inability to classify physiology. Physiologic treatment was associated with fewer antihypertensive doses (1.4±0.9 doses vs 1.6±1.4 doses; adjusted β -0.28, 95% CI, -0.42 to -0.14) and lower odds of medication conversion (2.5% vs 4.7%; adjusted odds ratio 0.48, 95% CI, 0.24-0.93) but no difference in time to nonsevere BP (31 minutes [interquartile range 16-66 minutes] vs 34 minutes [interquartile range 15-76 minutes]; adjusted hazard ratio 1.0, 95% CI, 0.9-1.2). Physiologic treatment of severe hypertension warrants further evaluation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antihypertensive Agents |2 NLM | |
| 650 | 7 | |a Hydralazine |2 NLM | |
| 650 | 7 | |a 26NAK24LS8 |2 NLM | |
| 650 | 7 | |a Labetalol |2 NLM | |
| 650 | 7 | |a R5H8897N95 |2 NLM | |
| 650 | 7 | |a Nifedipine |2 NLM | |
| 650 | 7 | |a I9ZF7L6G2L |2 NLM | |
| 700 | 1 | |a Blanchard, Christina T |e verfasserin |4 aut | |
| 700 | 1 | |a Subramaniam, Akila |e verfasserin |4 aut | |
| 700 | 1 | |a Sinkey, Rachel G |e verfasserin |4 aut | |
| 700 | 1 | |a Tita, Alan T |e verfasserin |4 aut | |
| 700 | 1 | |a Battarbee, Ashley N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Obstetrics and gynecology |d 1953 |g 143(2024), 2 vom: 01. Feb., Seite 277-280 |w (DE-627)NLM000021555 |x 1873-233X |7 nnns |
| 773 | 1 | 8 | |g volume:143 |g year:2024 |g number:2 |g day:01 |g month:02 |g pages:277-280 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/AOG.0000000000005472 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 143 |j 2024 |e 2 |b 01 |c 02 |h 277-280 | ||